BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22037410)

  • 1. The novel adenosine A2A antagonist Lu AA47070 reverses the motor and motivational effects produced by dopamine D2 receptor blockade.
    Collins LE; Sager TN; Sams AG; Pennarola A; Port RG; Shahriari M; Salamone JD
    Pharmacol Biochem Behav; 2012 Jan; 100(3):498-505. PubMed ID: 22037410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the adenosine A 2A antagonist KW 6002 (istradefylline) on pimozide-induced oral tremor and striatal c-Fos expression: comparisons with the muscarinic antagonist tropicamide.
    Betz AJ; Vontell R; Valenta J; Worden L; Sink KS; Font L; Correa M; Sager TN; Salamone JD
    Neuroscience; 2009 Sep; 163(1):97-108. PubMed ID: 19467297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The novel adenosine A(2A) antagonist prodrug MSX-4 is effective in animal models related to motivational and motor functions.
    Santerre JL; Nunes EJ; Kovner R; Leser CE; Randall PA; Collins-Praino LE; Lopez Cruz L; Correa M; Baqi Y; Müller CE; Salamone JD
    Pharmacol Biochem Behav; 2012 Oct; 102(4):477-87. PubMed ID: 22705392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conditional neural knockout of the adenosine A(2A) receptor and pharmacological A(2A) antagonism reduce pilocarpine-induced tremulous jaw movements: studies with a mouse model of parkinsonian tremor.
    Salamone JD; Collins-Praino LE; Pardo M; Podurgiel SJ; Baqi Y; Müller CE; Schwarzschild MA; Correa M
    Eur Neuropsychopharmacol; 2013 Aug; 23(8):972-7. PubMed ID: 22947264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of adenosine antagonists in two models of parkinsonian tremor.
    Trevitt J; Kawa K; Jalali A; Larsen C
    Pharmacol Biochem Behav; 2009 Nov; 94(1):24-9. PubMed ID: 19602422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The non-selective adenosine antagonist theophylline reverses the effects of dopamine antagonism on tremor, motor activity and effort-based decision-making.
    Pardo M; Paul NE; Collins-Praino LE; Salamone JD; Correa M
    Pharmacol Biochem Behav; 2020 Nov; 198():173035. PubMed ID: 32910928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nucleus accumbens and effort-related functions: behavioral and neural markers of the interactions between adenosine A2A and dopamine D2 receptors.
    Farrar AM; Segovia KN; Randall PA; Nunes EJ; Collins LE; Stopper CM; Port RG; Hockemeyer J; Müller CE; Correa M; Salamone JD
    Neuroscience; 2010 Apr; 166(4):1056-67. PubMed ID: 20096336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenosine A(2A) receptor antagonism reverses the effects of dopamine receptor antagonism on instrumental output and effort-related choice in the rat: implications for studies of psychomotor slowing.
    Farrar AM; Pereira M; Velasco F; Hockemeyer J; Müller CE; Salamone JD
    Psychopharmacology (Berl); 2007 Apr; 191(3):579-86. PubMed ID: 17072593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenosine A2A receptor antagonism and genetic deletion attenuate the effects of dopamine D2 antagonism on effort-based decision making in mice.
    Pardo M; Lopez-Cruz L; Valverde O; Ledent C; Baqi Y; Müller CE; Salamone JD; Correa M
    Neuropharmacology; 2012 Apr; 62(5-6):2068-77. PubMed ID: 22261384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential actions of adenosine A1 and A2A antagonists on the effort-related effects of dopamine D2 antagonism.
    Salamone JD; Farrar AM; Font L; Patel V; Schlar DE; Nunes EJ; Collins LE; Sager TN
    Behav Brain Res; 2009 Jul; 201(1):216-22. PubMed ID: 19428636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tremorolytic effects of adenosine A2A antagonists: implications for parkinsonism.
    Salamone JD; Betz AJ; Ishiwari K; Felsted J; Madson L; Mirante B; Clark K; Font L; Korbey S; Sager TN; Hockemeyer J; Muller CE
    Front Biosci; 2008 May; 13():3594-605. PubMed ID: 18508458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the selective adenosine A2A receptor antagonist, SCH 412348, on the parkinsonian phenotype of MitoPark mice.
    Smith KM; Browne SE; Jayaraman S; Bleickardt CJ; Hodge LM; Lis E; Yao L; Rittle SL; Innocent N; Mullins DE; Boykow G; Reynolds IJ; Hill D; Parker EM; Hodgson RA
    Eur J Pharmacol; 2014 Apr; 728():31-8. PubMed ID: 24486705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The adenosine A2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism.
    Correa M; Wisniecki A; Betz A; Dobson DR; O'Neill MF; O'Neill MJ; Salamone JD
    Behav Brain Res; 2004 Jan; 148(1-2):47-54. PubMed ID: 14684247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deep brain stimulation of the subthalamic nucleus reverses oral tremor in pharmacological models of parkinsonism: interaction with the effects of adenosine A2A antagonism.
    Collins-Praino LE; Paul NE; Ledgard F; Podurgiel SJ; Kovner R; Baqi Y; Müller CE; Senatus PB; Salamone JD
    Eur J Neurosci; 2013 Jul; 38(1):2183-91. PubMed ID: 23600953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of subtype-selective adenosine receptor antagonists on basal or haloperidol-regulated striatal function: studies of exploratory locomotion and c-Fos immunoreactivity in outbred and A(2A)R KO mice.
    Pardo M; López-Cruz L; Valverde O; Ledent C; Baqi Y; Müller CE; Salamone JD; Correa M
    Behav Brain Res; 2013 Jun; 247():217-26. PubMed ID: 23557694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist.
    Sams AG; Mikkelsen GK; Larsen M; Langgård M; Howells ME; Schrøder TJ; Brennum LT; Torup L; Jørgensen EB; Bundgaard C; Kreilgård M; Bang-Andersen B
    J Med Chem; 2011 Feb; 54(3):751-64. PubMed ID: 21210664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The adenosine A2A antagonist MSX-3 reverses the effort-related effects of dopamine blockade: differential interaction with D1 and D2 family antagonists.
    Worden LT; Shahriari M; Farrar AM; Sink KS; Hockemeyer J; Müller CE; Salamone JD
    Psychopharmacology (Berl); 2009 Apr; 203(3):489-99. PubMed ID: 19048234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The vesicular monoamine transporter (VMAT-2) inhibitor tetrabenazine induces tremulous jaw movements in rodents: implications for pharmacological models of parkinsonian tremor.
    Podurgiel SJ; Nunes EJ; Yohn SE; Barber J; Thompson A; Milligan M; Lee CA; López-Cruz L; Pardo M; Valverde O; Lendent C; Baqi Y; Müller CE; Correa M; Salamone JD
    Neuroscience; 2013 Oct; 250():507-19. PubMed ID: 23867769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CSC counteracts l-DOPA-induced overactivity of the corticostriatal synaptic ultrastructure and function in 6-OHDA-lesioned rats.
    Huang YX; Luo WF; Li D; Hu WD; Liu CF
    Brain Res; 2011 Feb; 1376():113-21. PubMed ID: 21195062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tremorolytic effects of safinamide in animal models of drug-induced parkinsonian tremor.
    Podurgiel S; Collins-Praino LE; Yohn S; Randall PA; Roach A; Lobianco C; Salamone JD
    Pharmacol Biochem Behav; 2013 Apr; 105():105-11. PubMed ID: 23360954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.